Is uniQure’s (QURE) AMT-130 UK Push Quietly Rewriting Its Risk Profile and R&D Strategy?

In April 2026, uniQure announced plans to seek UK regulatory approval for AMT-130, its gene therapy for Huntington’s disease, supported by Phase 1/2 data indicating a very large slowing of disease progression at the high dose. The company also aims to meet the US FDA to discuss a potential Phase 3 trial, highlighting how AMT-130 is moving closer to a possible first-in-class treatment pathway for this rare neurodegenerative disorder. We’ll now examine how this move toward UK approval for…Read More